From the beginning of XXI century, a new direction was clearly marked out, which focused clinicians' attention on the role of endothelial dysfunction (ED) in the formation of chronic heart failure (CHF) (1, 2, 3) . It is commonly known that in the pathogenesis of chronic heart failure, along with neuroendocrine regulation disorders -activation of the sympathoadrenal system (SAS) and renin -angiotensin -aldosterone system (RAAS), endothelial dysfunction plays an important role (4, 5) , which is characterized by reduced dilation of blood vessels and enhanced vasoconstriction as a result of depressed NO formation, activation of cytokine systems and disorders of vascular wall thrombo -resistance. At present, it is proven that reduced endothelium -dependent vasodilation of vessels, changes in the content of humoral markers of blood, such as von Willebrand factor (VWF), tumor necrosis factor, cytokine and endothelin serve as markers of endothelial dysfunction (6,7).
To date, beta-blockers (BAB), along with angiotensin converting enzyme inhibitors are the primary means of CHF treatment. At present, it is established that BABs have a blocking effect not only on the SAS, but also on several other neurohormonal systems responsible for the progression of heart failure, including -RAAS, endothelin and cytokine systems (8, 9, 10) .
Methods
We examined 52 patients with postinfarction cardiosclerosis, complicated by chronic heart failure -men aged 38-60 years at the Tashkent Medical Academy, I Clinic, Cardiology Department. Following written informed consent, patients having myocardial infarction with Q wave within 2 months -3 years were randomly assigned to receive bisoprolol or carvedilol. NYHA classes were determined analyzing six-minute walk test (6′WT)and the scale of assessment of clinical status (SACS). The study did not include patients with diabetes mellitus, cardiac arrhythmias, and chronic obstructive pulmonary disease. All the patients were divided into two groups: 1 -51 patients treated on basic therapy (ACE inhibitors, spironolactone, nitrates, aspirin, if necessary, loop diuretics) -and highly selective BAB -bisoprolol ("Concor" Company « Nycomed », Germany); 2 -49 patients treated on basic therapy and BAB, which has α1-, β1-and β2 -blocking properties -carvedilol ("Dilatrend" Company « Roche », Switzerland). BAB titration was performed from 1.25 to 10 mg / day assigned dose for -bisoprolol and 3,125 to 25-50 mg / day assigned dose for -carvedilol. Control group consisted of 20 healthy volunteers.
The study was approved by the local Ethics Committee.
Vasomotor endothelial function of the brachial artery was assessed by Doppler screening on the unit -Acuson 128 (U.S.) with 7 MHz linear transducer. Brachial artery (BA) was visualized in the longitudinal section, 2-5 cm proximal to the elbow. Blood vessel regulating function of endothelium was studied by assessing endothelium dependant and endothelium independent vasodilation (EDVD and EIVD). Von Willebrand factor in blood plasma was determined by enzyme-linked immunosorbent assay (ELISA) using reagents of the company "RENAM" analyzer -"Vidas" (France).
Statistical processing of research results was performed on a personal computer type IBM PC / AT using a spreadsheet package EXCEL 6,0 Windows-95. Parameters were described in the form of: arithmetic mean ± standard deviation (M ± SD).
Results
Baseline 6′WT performance showed that all patients, regardless of NYHA Classes of CHF, had low tolerance to physical load. Patients of the first and second groups with NYHA Class II of CHF had less tolerance by 1,4 and 1,3 times, respectively, compared to Class I, while Class III -by 2,0 and 2,1 times. Evaluation of the clinical status of examined patients by SACS showed that patients in the first group with Class I CHF had this index as 3,4 ± 0,31 points and in the second group -3,5 ± 0,26 points, respectively. The study revealed increasing SACS indices along with progression of chronic heart failure: its indices were higher by 58.8% and 147% in patients of the first group with Classes II and III CHF, respectively, compared to the datum of patients with Class I CHF.
After 3 months of observation, 6′WT results showed a significant increase in the distance in all patients, after 6 months this index was normalized in patients with Class I CHF, while Classes II and III CHF had increased walked distances by 29.5 and 30.3% (P <0.001) in the first group and 35,7 and 40,1% (P < 0,001) -in the second group. Initial SACS results showed that the patients of the first and second groups had 3,4 ± 1,08 and 3,5 ± 0,90 points, respectively. And it increased with the progression of chronic heart failure: it exceeded Class I CHF by 58.8 and 147% (P <0.001) and by 57 and 142% (P <0.001) in Classes II and III CHF, respectively. Three and six months of bisoprolol treatment improved the clinical status of the patients, the indices of the baseline SACS decreased by 20,5 and 35,2% (P <0.01), 12,9 and 35,2%, 15% and 30.9% (P < 0,001) in respective Classes I-III CHF. At the same time, complex treatment with carvedilol also significantly improved the clinical status of the patients. The studied indices decreased from baseline in Classes I-III CHF by 31 and 51.4% (P <0.001), 25.4 and 45% (P <0.001), 21.2 and 40% (P <0.001), in respective 3 and 6 months of observation.
To assess the vasodilating function of endothelium, the examined patients had the parameters of blood flow studied in the brachial artery by evaluating EDVD and EIVD. In patients with Class I CHF, BA diameter was less compared to the control group by (9, 10) .
Against the background of complex treatment with bisoprolol and carvedilol in patients of first and second groups with Class I CHF after 6 months, EDVD increased significantly -by 18,3 and 38,8% (P <0.05), respectively. Noted an increase in the diameter of the BA by 4,6 and 11,9% (P <0.005) on the background of bisoprolol and carvedilol. Systolic blood velocity accelerated by 3.6 and 12.8%, and diastolic by 10.5 and 55%. Average blood flow velocity accelerated significantly from initial by 4,9 and 20,9% (P <0.001). Resistive index decreased by 1.3 and 11.8%, pulse index by -4,2 and 17,8%. The sensitivity of the BA to the shear stress increased significantly by 30 and 40% (P <0.005), in the first and second groups, respectively. Long-term bisoprolol therapy in patients with Class II CHF promoted an increase of EDVD by only 11,1%, when after carvedilol, it increased significantly -35.7% (P <0.05), the diameter of BA increased as well: after bisoprolol by 10,5%, and carvedilol by 12.8% (P <0.001). Systolic blood velocity accelerated by 1,4 and 7,9%, diastolic -13,5 and 35,4%, the average flow velocity accelerated by 3,6 and 12,6% (P <0.001) from the initial.
Resistive index decreased by 3,8 and 6,3%, pulse index by 5,4 and 10,6%. The sensitivity of the BA to the shear stress in the first group is almost unchanged, while in the second group it increased by 33.3% (P <0.001). Against the background of complex treatment with bisoprolol and carvedilol in patients with Class III CHF after 6 months, EDVD increased by 34 and 60.4% (P <0.02), respectively, compared to the initial datum. The diameter of the BA lengthened by 6 and 8.8%, respectively (P <0.01). Systolic blood velocity accelerated by 2,7 and 2,9%, diastolic by 15.2 and 30%, the average flow velocity by 4,6% and 6,7% (P <0.01) after administration of bisoprolol and carvedilol, respectively,.
Changes in levels of von Willebrand factor is experimentally and clinically proven marker, reflecting the functional state of the endothelium (12, 13 The positive effect of carvedilol in patients with Class III CHF on the parameters of endothelial dysfunction is associated with its additional α1-adrenoblocking, and antioxidant properties of the drug and conforms to datum of other researchers (13, 14) .
Conclusions
Long-term therapy with carvedilol and bisoprolol promotes correction of endothelial dysfunction, expressing as improving endothelium -dependent vasodilation, reducing vascular tone, accelerating blood velocity, reducing von Willebrand factor in patients with NHYA Classes I-II of CHF. In patients with Class III CHF, six-month carvedilol therapy significantly improves endothelium-dependent vasodilation, reduces vascular tone, functional activity of platelets and von Willebrand factor level.
